S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.

Cullinan Oncology (CGEM) Earnings Date, Estimates & Call Transcripts

$9.49
-0.12 (-1.25%)
(As of 09/22/2023 ET)
Compare
Today's Range
$9.20
$9.73
50-Day Range
$9.49
$11.35
52-Week Range
$7.78
$13.98
Volume
148,048 shs
Average Volume
193,962 shs
Market Capitalization
$405.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.50

Earnings Summary

Upcoming
Earnings Date
Nov. 13Estimated
Actual EPS
(Aug. 10)
-$0.82 Beat By $0.17
Consensus EPS
(Aug. 10)
-$0.99
Skip Charts & View Estimated and Actual Earnings Data

CGEM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CGEM Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Cullinan Oncology Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($1.14)($0.67)($0.91)
Q2 20232($0.74)($0.68)($0.71)
Q3 20232($1.47)($0.82)($1.15)
Q4 20232($1.50)($0.96)($1.23)
FY 20238($4.85)($3.13)($3.99)

CGEM Earnings Date and Information

Cullinan Oncology last issued its earnings results on August 10th, 2023. The reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.99) by $0.17. Cullinan Oncology has generated ($3.37) earnings per share over the last year (($3.37) diluted earnings per share). Earnings for Cullinan Oncology are expected to decrease in the coming year, from ($4.14) to ($4.23) per share. Cullinan Oncology has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 13th, 2023 based off prior year's report dates.

Cullinan Oncology Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/13/2023
Estimated)
------- 
8/10/2023Q2 2023($0.99)($0.82)+$0.17($0.82)--
5/11/2023Q1 2023($0.84)($1.42)($0.58)($1.42)--
3/9/2023Q4 2022($0.65)($0.59)+$0.06($0.59)--
11/14/2022Q3 2022($0.97)($0.54)+$0.43($0.54)--
8/10/2022Q2 2022$5.47($2.20)($7.67)($8.17)--
5/16/2022Q1 2022($0.61)($0.27)+$0.34($0.27)--
3/17/2022Q4 2021($0.47)($0.74)($0.27)($0.74)--
11/9/2021Q3($0.4230)($0.40)+$0.0230($0.40)--
8/9/2021Q2 2021($0.42)($0.44)($0.02)($0.36)--












Cullinan Oncology Earnings - Frequently Asked Questions

When is Cullinan Oncology's earnings date?

Cullinan Oncology has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 13th, 2023 based off last year's report dates. Learn more on CGEM's earnings history.

Did Cullinan Oncology beat their earnings estimates last quarter?

In the previous quarter, Cullinan Oncology (NASDAQ:CGEM) reported ($0.82) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.99) by $0.17. Learn more on analysts' earnings estimate vs. CGEM's actual earnings.

How much revenue does Cullinan Oncology generate each year?

Cullinan Oncology (NASDAQ:CGEM) has a recorded annual revenue of $18.94 million.

How much profit does Cullinan Oncology generate each year?

Cullinan Oncology (NASDAQ:CGEM) has a recorded net income of $111.21 million. CGEM has generated -$3.37 earnings per share over the last four quarters.

What is Cullinan Oncology's EPS forecast for next year?

Cullinan Oncology's earnings are expected to decrease from ($4.14) per share to ($4.23) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:CGEM) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -